Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/17512433.2021.1856655 http://scihub22266oqcxt.onion/10.1080/17512433.2021.1856655 33252992!7784780!33252992     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Rev+Clin+Pharmacol 2021 ; 14 (1): 95-103 Nephropedia Template TP {{tp|p=33252992|t=2021. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications |pdf=|usr=}}{{33252992}} gab.com Text Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications JO: Expert Rev Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33252992 #FOAvip Objectives: Remdesivir has shown promise in the management of patients with COVID-19 although recent studies have shown concerns with its effectiveness in practice. Despite this there is a need to document potential adverse drug events (ADEs) to guide future decisions as limited ADE data available before the COVID-19 pandemic. Methods: Interrogation of WHO VigiBase(R) from 2015 to 2020 coupled with published studies of ADEs in COVID-19 patients. The main outcome measures are the extent of ADEs broken down by factors including age, seriousness, region and organ. Results: A total 1086 ADEs were reported from the 439 individual case reports up to July 19, 2020, in the VigiBase(R), reduced to 1004 once duplicates were excluded. Almost all ADEs concerned COVID-19 patients (92.5%), with an appreciable number from the Americas (67.7%). The majority of ADEs were from males > 45 years and were serious (82.5%). An increase in hepatic enzymes (32.1%), renal injury (14.4%), rise in creatinine levels (11.2%), and respiratory failure (6.4%) were the most frequently reported ADEs. Conclusions: Deterioration of liver and kidney function are frequently observed ADEs with remdesivir; consequently, patients should be monitored for these ADEs. The findings are in line with ADEs included in regulatory authority documents. Twit Text FOAVip Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications ????Expert Rev Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33252992 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33252992 #FOAvip English Wikipedia <ref>{{Cite pmid|33252992}}</ref> Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications #MMPMID33252992 Charan J; Kaur RJ; Bhardwaj P; Haque M; Sharma P; Misra S; Godman B Expert Rev Clin Pharmacol 2021[Jan]; 14 (1): 95-103 PMID33252992show ga Objectives: Remdesivir has shown promise in the management of patients with COVID-19 although recent studies have shown concerns with its effectiveness in practice. Despite this there is a need to document potential adverse drug events (ADEs) to guide future decisions as limited ADE data available before the COVID-19 pandemic. Methods: Interrogation of WHO VigiBase(R) from 2015 to 2020 coupled with published studies of ADEs in COVID-19 patients. The main outcome measures are the extent of ADEs broken down by factors including age, seriousness, region and organ. Results: A total 1086 ADEs were reported from the 439 individual case reports up to July 19, 2020, in the VigiBase(R), reduced to 1004 once duplicates were excluded. Almost all ADEs concerned COVID-19 patients (92.5%), with an appreciable number from the Americas (67.7%). The majority of ADEs were from males > 45 years and were serious (82.5%). An increase in hepatic enzymes (32.1%), renal injury (14.4%), rise in creatinine levels (11.2%), and respiratory failure (6.4%) were the most frequently reported ADEs. Conclusions: Deterioration of liver and kidney function are frequently observed ADEs with remdesivir; consequently, patients should be monitored for these ADEs. The findings are in line with ADEs included in regulatory authority documents. |*Adverse Drug Reaction Reporting Systems[MESH] |*COVID-19 Drug Treatment[MESH] |*Databases, Factual[MESH] |*SARS-CoV-2[MESH] |Adenosine Monophosphate/adverse effects/*analogs & derivatives/therapeutic use[MESH] |Alanine/adverse effects/*analogs & derivatives/therapeutic use[MESH] |Antiviral Agents/*adverse effects/therapeutic use[MESH] |Humans[MESH]Rapid review of suspected adverse drug events due to remdesivir in the(epmc).pdf DeepDyve Pubget Overpricing